AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1881997
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg carbamazepine
Trial: 6693665
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bitolterol and theophylline
Trial: 20232036
Drug: GRV =
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GRV = 500 ml
Trial: 20232036
Drug: GRV =
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GRV = 200 ml
Trial: 16969601
Drug: Prepped CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepped CT colonography with low fiber diet, tagging, and magnesium citrate cleansing preparation
Trial: 15026800
Drug: Oral capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (1250 mg m(‐2) twice daily, days 1‐14 every 21 days; n=603)
Trial: 15026800
Drug: Intravenous 5-fluorouracil/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV; Mayo Clinic regimen; n=604)
Trial: 15026800
Drug: Intravenous 5-fluorouracil/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV)
Trial: 25495503
Drug: Basic advice
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic advice regarding compliance with therapy and weight loss
Trial: 16842456
Drug: NSAID prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID prescription with diagnostic codes for UGIE and endoscopic procedural codes
Trial: 16842456
Drug: Algorithm validation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm validation in patients with overlapping NSAID prescription
Trial: 12957759
Drug: Crystalloid cardioplegic
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid cardioplegic solution (Group A, n=9)
Trial: 12957759
Drug: Warm blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm blood cardioplegic solution (Group B, n=8)
Trial: 8258611
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, administered four times at 4-hour intervals)
Trial: 3929584
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg once daily) plus labetalol placebo
Trial: 3929584
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg twice daily) plus atenolol placebo
Trial: 29210513
Drug: CD gel
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD gel with 1 mg/2 mL budesonide
Trial: 29210513
Drug: CD gel
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD gel (without budesonide)
Trial: 29210513
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid cream
Trial: 20185012
Drug: Ezetimibe added
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe added to atorvastatin 10 mg for 12 weeks
Trial: 20185012
Drug: Ezetimibe added
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe added to atorvastatin 10 mg
Trial: 20185012
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg or atorvastatin 40 mg
Trial: 17319927
Drug: Omeprazole at
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole at half the starting dose, once daily before breakfast
Trial: 17319927
Drug: Ranitidine 10
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 10 mg/kg/day, divided in two doses
Trial: 15151791
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (IG) received a telephone call at 2 weeks, 2 months and 4 months in addition to normal treatment
Trial: 15151791
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) received normal treatment
Trial: 9752991
Drug: High WBF
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High WBF (13.5 g/day)
Trial: 9752991
Drug: Low WBF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low WBF (2 g/day)
Trial: 3589921
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 milligrams every six hours) and Gentamicin (loading dose of 2.0 milligrams per kilogram, then 1.5 milligrams per kilogram every eight hours)
Trial: 30704890
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B complex (B1, B6, and B12) once daily for 12 weeks
Trial: 29786677
Drug: Combined rehabilitative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined rehabilitative physiotherapeutic treatment including modulated sinusoidal currents, total wrapping with Rapan saline solution, and sedative inhalations of peony root extract.
Trial: 29786677
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment (control group).
Trial: 18673434
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 4 weeks
Trial: 17852859
Drug: BIO-THREE (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIO-THREE (9 tablets per day for 4 weeks)
Trial: 10386279
Drug: Isoflurane anesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane anesthesia (1.2% to 2.0% in 50% oxygen) with intravenous thiopental sodium (3 to 5 mg/kg) and succinylcholine (0.5 to 1.0 mg/kg) for tracheal intubation.
Trial: 6863643
Drug: Suberythemogenic UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suberythemogenic UVB with adjunctive coal tar
Trial: 31077576
Drug: Novel phosphodiesterase-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel phosphodiesterase-4 inhibitor (CHF6001)
Trial: 28296732
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg oxycodone
Trial: 28296732
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg oxycodone
Trial: 28296732
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg oxycodone
Trial: 28296732
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg oxycodone
Trial: 28296732
Drug: 0.159 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.159 mg/kg oxycodone (ED95)
Trial: 28296732
Drug: 0.020 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.020 mg/kg oxycodone (ED50)
Trial: 28296732
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg/kg oxycodone)
Trial: 26567274
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Bupropion Sustained Release
Trial: 26567274
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Bupropion Sustained Release
Trial: 23103313
Drug: Seizure free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seizure free status, one or no antiepileptic drug (AED), EEG without epileptiform abnormalities
Trial: 23103313
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of enzyme‐inducing AEDs
Trial: 17878762
Drug: High-dose hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hydrocortisone
Trial: 17878762
Drug: Bradykinin, acetylcholine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin, acetylcholine, sodium nitroprusside infusions
Trial: 3542618
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with one or two daily doses of insulin (Group A)
Trial: 3542618
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment with nine daily injections of fast‐acting insulin for ten days and for 7 days after 15 months (Group B)
Trial: 3542618
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment with nine daily injections of fast‐acting insulin (Group B)
Trial: 28855419
Drug: PRO40 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO40 (40 g casein)
Trial: 28855419
Drug: PRO20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO20 (20 g casein)
Trial: 28855419
Drug: PRO20+LEU (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO20+LEU (20 g casein plus 1.5 g leucine)
Trial: 25543822
Drug: Ceramide 2-containing
RxNorm normalized name: ceramide 2
DrugBank: Ceramide NG (DB14706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide 2-containing hydrocolloid dressings with varying amounts of tackifying agent (TA)
Trial: 10669692
Drug: RCP-directed treatments
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCP-directed treatments (Firm A, n = 239)
Trial: 10669692
Drug: Physician-directed treatments
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-directed treatments (Firms B and C)
Trial: 28851443
Drug: Two approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two approaches to speech and language therapy (SLT)
Trial: 21346062
Drug: Dietary methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary methionine restriction (MR) at 2 mg methionine/kg body weight per day
Trial: 21346062
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 33 mg methionine/kg body weight per day
Trial: 11128915
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (with and without DFDBA)
Trial: 9069293
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation therapy (EBRT) alone (Group 1)
Trial: 9069293
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant combination therapy (LHRH‐agonist + Flutamide) prior to EBRT (Group 2)
Trial: 9069293
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy 3 months before, during, and 6 months after EBRT (Group 3)
Trial: 8450178
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose L-carnitine (6 gr per day for two weeks)
Trial: 30149474
Drug: Gastric lavage
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric lavage (GL) with 10 ml/kg of normal saline
Trial: 28598927
Drug: ANI-guided fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ANI-guided fentanyl administration
Trial: 8777885
Drug: Cryotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy (standard therapy using cool packs)
Trial: 7116616
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (aerosol and powder)
Trial: 7116616
Drug: Counting of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counting of sneezes after medication
Trial: 21480950
Drug: telcagepant 500
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 500 mg
Trial: 7437212
Drug: Normovolaemic haemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolaemic haemodilution (23 +/- 2 ml/kg of blood withdrawn, replaced by twice volume with 4% albumin and Ringer lactate solution)
Trial: 30851351
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen (HBO) administered in 30 daily dives at 100% oxygen to a pressure of 2.4 atmospheres absolute for 80 to 90 minutes.
Trial: 30851351
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBO treatment).
Trial: 9234029
Drug: Women who
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who intentionally omitted or reduced insulin
Trial: 3688570
Drug: IgG anti-cow's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG anti-cow's milk antibody
Trial: 3688570
Drug: Cow's milk-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk-specific IgG antibody
Trial: 29172715
Drug: Telemonitoring: weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring: weekly assessment of transmitted HBP by physicians and treatment adjustment upon office visits
Trial: 29172715
Drug: Telemedicine: online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine: online communication instead of office visits to adjust medication using telemonitored HBP
Trial: 22551811
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg hemagglutinin (HA) alone
Trial: 22551811
Drug: 1.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 μg HA and Matrix M adjuvant (50 μg)
Trial: 22551811
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg HA and Matrix M adjuvant (50 μg)
Trial: 22551811
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg HA and Matrix M adjuvant (50 μg)
Trial: 18403736
Drug: DP‐b99 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP‐b99 (1 mg/kg per day for 4 days)
Trial: 11808836
Drug: Sarpogrelate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate (200 mg, oral administration)
Trial: 7723301
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride 50 mg intranasally
Trial: 7723301
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride 126 mg intranasally
Trial: 7723301
Drug: Sweat patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweat patch technology
Trial: 7723301
Drug: Nondrug users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondrug users wearing patches
Trial: 6355207
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day of amitriptyline
Trial: 6355207
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day of phenelzine
Trial: 31249253
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg administered sublingually 50 minutes before surgery
Trial: 31249253
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered sublingually 50 minutes before surgery
Trial: 19110224
Drug: Desvenlafaxine 150
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 150 mg/d
Trial: 16398436
Drug: Qianggu capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggu capsules (QGC), 1 capsule (180 mg) each time, three times a day for three months
Trial: 16398436
Drug: D-Cal Biocal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cal Biocal, 2 tablets (1500 mg) each time, once daily for three months
Trial: 8590616
Drug: ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritanserin (10 mg)
Trial: 2672380
Drug: nimesulide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (200 mg/day p.o.)
Trial: 24196331
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (1319 nm, 1064 nm, and BroadBand Light)
Trial: 21530095
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of zinc sulfate orally in water daily for 6 weeks + one capsule of vitamin B-complex + one capsule of vitamin A or E (first 10 days)
Trial: 21530095
Drug: Proposed placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proposed placebo-controlled trials with incremental doses of zinc sulfate along with magnesium and selenium
Trial: 18505442
Drug: Iopanoic acid
RxNorm normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopanoic acid (IA) 3 g/day for 7 days
Trial: 18505442
Drug: Carbimazole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole 30 mg/day for 1 month
Trial: 9135951
Drug: Basic amino
RxNorm normalized name: Paired basic amino acid residue cleaving enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic amino acids (L-arginine 2 g/day plus L-lysine 0.5 g/day)
Trial: 8031342
Drug: morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (2 mg.ml‐1) with droperidol (0.2 mg.ml‐1)
Trial: 8031342
Drug: morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine alone (2 mg.ml‐1)
Trial: 3003445
Drug: Hydrochlorothiazide (HTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HTZ) administration, 25 mg 12-hrly for 18 days
Trial: 27875286
Drug: Immunomodulatory formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory formula (IF) 400 mL/d for 10 days prior to surgery
Trial: 22357739
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of vitamin D and calcium-fortified soft white cheese (2 servings of 100 g daily for 6 weeks)
Trial: 16320709
Drug: Dextran treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran treatment
Trial: 10586393
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenous infusion (18 min)
Trial: 10586393
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg oral solution
Trial: 10586393
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg orally administered capsule
Trial: 8767364
Drug: New guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New guidelines for thrombolytic therapy
Trial: 1841935
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) 60 mg/kg
Trial: 1841935
Drug: Non-treatment (NT)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment (NT)
Trial: 26414022
Drug: Avagacestat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat (50 mg/d)
Trial: 26414022
Drug: Avagacestat (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat (125 mg/d)
Trial: 23617621
Drug: Modified treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified treatment (ModTx)
Trial: 23617621
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (StTx)
Trial: 21543538
Drug: Controlled research
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled research meals with lower protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) reduced by 0.2 to 0.3 g · kg(‐1) · d(‐1))
Trial: 21543538
Drug: Controlled research
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled research meals with higher protein intake (0.9-1.1 g protein · kg(‐1) · d(‐1) increased by 0.2 g · kg(‐1) · d(‐1))
Trial: 19056566
Drug: Monosodium L-glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium L-glutamate (MSG) added to a protein-rich liquid meal
Trial: 19056566
Drug: Monosodium L-glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium L-glutamate (MSG) added to a carbohydrate meal
Trial: 19056566
Drug: Monosodium L-glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium L-glutamate (MSG) added to noncaloric water
Trial: 11407289
Drug: Ketamine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.5 mg/kg i.v.
Trial: 11407289
Drug: Thiamylal 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 5 mg/kg i.v.
Trial: 9427902
Drug: Continuous phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous phenobarbital therapy
Trial: 3559333
Drug: Regimen I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I: rifampin 600 mg once a month for 6 months with dapsone 100 mg daily